Cargando…

Reply: Antifungal Prophylaxis

Detalles Bibliográficos
Autores principales:	Pennington, Kelly M., Razonable, Raymund R., Kennedy, Cassie C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Thoracic Society 2021
Materias:	Letters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8522291/ https://www.ncbi.nlm.nih.gov/pubmed/33901414 http://dx.doi.org/10.1513/AnnalsATS.202104-445LE

Ejemplares similares

Antifungal Prophylaxis
por: Johnson, Douglas Clark, et al.
Publicado: (2021)

In reply—The “Perfect Cytokine Storm” of COVID-19
por: Vijayvargiya, Prakhar, et al.
Publicado: (2020)

Antifungal prophylaxis in critically ill patients
por: Silvestri, Luciano, et al.
Publicado: (2008)

461 Clostridium difficile Infection and Mortality in Lung Transplant Recipients: A Single-Center Retrospective Cohort Study
por: Chong, Pearlie P., et al.
Publicado: (2014)

454 Cytomegalovirus (CMV) Disease after Lung Transplantation (LT) is associated with increased mortality despite Extended Antiviral Prophylaxis
por: Beam, Elena, et al.
Publicado: (2014)

Reply: Antimicrobial Prophylaxis in Extracorporeal Membrane Oxygenation: Is the Debate Still Open?
por: Kondo, Yutaka, et al.
Publicado: (2022)

Authors' Reply
por: Pennington, Justin D., et al.
Publicado: (2019)

Characterization of Early-Onset Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Patients Who Received Tixagevimab-Cilgavimab Prophylaxis
por: Ordaya, Eloy E, et al.
Publicado: (2022)

Genotypic and predicted phenotypic analysis of SARS-COV-2 Omicron subvariants in immunocompromised patients with COVID-19 following tixagevimab-cilgavimab prophylaxis
por: Ordaya, Eloy E., et al.
Publicado: (2023)

Antiviral Drugs for Viruses Other Than Human Immunodeficiency Virus
por: Razonable, Raymund R.
Publicado: (2011)

Antifungal Prophylaxis in Immunocompromised Patients
por: Vazquez, Lourdes
Publicado: (2016)

445 Epidemiology and Outcomes of Clostridium difficile Infections in Heart and Heart-lung Transplant Recipients
por: Bruminhent, Jackrapong, et al.
Publicado: (2014)

Cytomegalovirus Infections in Solid Organ Transplantation: A Review
por: Ramanan, Poornima, et al.
Publicado: (2013)

1565. Lymphocyte Subsets as Predictors of Cytomegalovirus Infection After Transplantation
por: Meesing, Atibordee, et al.
Publicado: (2018)

Absolute Lymphocyte Count Thresholds: A Simple, Readily Available Tool to Predict the Risk of Cytomegalovirus Infection After Transplantation
por: Meesing, Atibordee, et al.
Publicado: (2018)

COVID-19 and Solid Organ Transplantation: Role of Anti-SARS-CoV-2 Monoclonal Antibodies
por: Dhand, Abhay, et al.
Publicado: (2022)

Editorial: Neutralizing Antibodies in the Prevention and Treatment of COVID-19
por: Razonable, Raymund R., et al.
Publicado: (2022)

Authors’ Reply - Antifungal Resistance in Dermatology
por: Pai, Varadraj, et al.
Publicado: (2019)

Authors' Reply
por: Fluit, C. R. M. G., et al.
Publicado: (2010)

Authors’ reply to Rayter
por: Dixon, J Michael, et al.
Publicado: (2015)

Lung Transplantation in Systemic Sclerosis: a Practice Survey of United States Lung Transplant Centers
por: Sehgal, Sameep, et al.
Publicado: (2021)

Letermovir and inhibitors of the terminase complex: a promising new class of investigational antiviral drugs against human cytomegalovirus
por: Melendez, Dante P, et al.
Publicado: (2015)

1536. Donor-Derived Mycobacterium tuberculosis Infection After Solid-Organ Transplantation: A Comprehensive Review
por: Abad, Cybele Lara, et al.
Publicado: (2018)

Letermovir for the prevention of cytomegalovirus infection and disease in transplant recipients: an evidence-based review
por: El Helou, Guy, et al.
Publicado: (2019)

Non-tuberculous mycobacterial infections in solid organ transplant recipients: An update
por: Abad, Cybele L., et al.
Publicado: (2016)

Stewardship of COVID-19 volunteers by nested trial design
por: Gottlieb, Robert L, et al.
Publicado: (2022)

Coronavirus Disease 2019 Management Strategies in Solid Organ Transplant Recipients
por: Mendoza, Maria Alejandra, et al.
Publicado: (2023)

Reply
por: Alrashed, Abdulaziz M.
Publicado: (2012)

REPLY BY THE AUTHORS: Re: Antibiotic prophylaxis prior to urodynamic study in patients with traumatic spinal cord injury. Is there an indication?
por: da Silva, Marcello Torres, et al.
Publicado: (2019)

Reply
por: Abu-Zidan, Fikri M., et al.
Publicado: (2012)

Micafungin as antifungal prophylaxis in non-transplanted haemotological patients
por: Villaescusa, Teresa, et al.
Publicado: (2020)

The Authors Reply
por: Andeen, Nicole K., et al.
Publicado: (2020)

1552. Absolute Lymphocyte Threshold: A Simple Readily Available Tool to Predict Risk of Cytomegalovirus Infection After Transplantation
por: Meesing, Atibordee, et al.
Publicado: (2018)

A Collaborative Multidisciplinary Approach to the Management of Coronavirus Disease 2019 in the Hospital Setting
por: Razonable, Raymund R., et al.
Publicado: (2020)

Breakthrough COVID-19 and casirivimab-imdevimab treatment during a SARS-CoV-2 B1.617.2 (Delta) surge
por: Bierle, Dennis M., et al.
Publicado: (2021)

Clinical Prioritization of Antispike Monoclonal Antibody Treatment of Mild to Moderate COVID-19
por: Razonable, Raymund R., et al.
Publicado: (2022)

Reply to: “Does currently recommended maternal antiviral prophylaxis against mother-to-child transmission of hepatitis B virus require enhancement?”
por: Matthews, Philippa C., et al.
Publicado: (2023)

Antifungal prophylaxis with posaconazole vs. fluconazole or itraconazole in pediatric patients with neutropenia
por: Döring, M., et al.
Publicado: (2015)

604 Risk Factors for Cytomegalovirus (CMV) Reactivation in CMV-seropositive Liver Transplant Patients
por: Bruminhent, Jackrapong, et al.
Publicado: (2014)

Authors’ reply
por: Bharathi, M Jayahar, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_hu4m50955v06j5ldsknaepkphd